Keros Therapeutics (NASDAQ:KROS) Stock Rating Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen lowered shares of Keros Therapeutics (NASDAQ:KROS) from a sell rating to a strong sell rating in a research report report published on Saturday morning,Wall Street Zen reports.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Leerink Partners lowered their target price on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Zacks Research upgraded shares of Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 27th. Finally, Wells Fargo & Company reduced their price target on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Four equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $20.50.

Keros Therapeutics Price Performance

Shares of KROS opened at $11.28 on Friday. Keros Therapeutics has a 1-year low of $9.69 and a 1-year high of $22.55. The stock has a market cap of $223.68 million, a PE ratio of -3.05 and a beta of 1.12. The firm has a fifty day moving average price of $11.23 and a 200 day moving average price of $11.05.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. As a group, equities analysts expect that Keros Therapeutics will post -5.27 EPS for the current fiscal year.

Keros Therapeutics declared that its board has initiated a share buyback plan on Wednesday, September 9th that authorizes the company to buy back $5.00 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 2.3% of its shares through open market purchases. Share repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Insider Activity at Keros Therapeutics

In related news, insider Lorena Raquel Lerner sold 3,568 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total transaction of $36,714.72. Following the completion of the sale, the insider directly owned 27,559 shares of the company’s stock, valued at $283,582.11. This trade represents a 11.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 5,343 shares of company stock worth $54,985 in the last three months. 12.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after acquiring an additional 1,166 shares in the last quarter. Quantinno Capital Management LP raised its holdings in Keros Therapeutics by 12.5% during the first quarter. Quantinno Capital Management LP now owns 23,759 shares of the company’s stock worth $262,000 after purchasing an additional 2,639 shares in the last quarter. Legal & General Group Plc acquired a new stake in Keros Therapeutics in the second quarter valued at about $90,000. PDT Partners LLC purchased a new stake in Keros Therapeutics in the 2nd quarter valued at approximately $122,000. Finally, Lazard Asset Management LLC purchased a new stake in Keros Therapeutics in the 1st quarter valued at approximately $129,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-?) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.